Prism Medico & Pharmacy Ltd is seeking shareholder nod to redirect Rs 23 crore from its preferential issue. The funds will now be used to acquire up to 71.32% in Infuze Well Private Limited, a company setting up an LVP manufacturing facility. This strategic shift bypasses greenfield execution risk but involves a material related party transaction.
Prism Medico & Pharmacy Ltd. Reallocates Capital for Strategic Investment
Prism Medico & Pharmacy Ltd. plans to acquire up to 71.32% stake in Infuze Well Private Limited for Rs 23 crore.
Reader Takeaway: Capital allocation shift to related party investment; governance of RPTs requires scrutiny.
What just happened
Prism Medico and Pharmacy Ltd. has proposed a significant change in its capital allocation strategy. The company is seeking shareholder approval to divert Rs 23 crore, originally earmarked for establishing its own plant and machinery, towards acquiring a controlling stake of up to 71.32% in Infuze Well Private Limited (IWPL). This proposal is a key agenda item for the company's 24th Annual General Meeting (AGM), scheduled for September 19, 2026, which will be held via video conference. The company has also appointed M/s. SDK & Associates as its Secretarial Auditor for a term of five years, covering FY 2026-2031.
Why this matters
This capital reallocation represents a strategic pivot from developing its own manufacturing infrastructure to investing in an existing project. Management views acquiring a stake in IWPL, which is setting up a Large Volume Parenteral (LVP) manufacturing facility in Naraingarh, Haryana, as a